Register
Login:
Share:
Email Facebook Twitter

Tower CEO gives give operational update on Njonji development well Watch Here

Exclusive: InfraStrata CEO confirms 6 parties interested in offtake agreements
Tower CEO gives give operational update on Njonji development well


Astrazeneca Share Price (AZN)



Share Price Information for Astrazeneca (AZN)


Share Price: 6,204.00Bid: 6,207.00Ask: 6,208.00Change: 0.00 (0.00%)No Movement on Astrazeneca
Spread: 1.00Spread as %: 0.02%Open: 6,182.00High: 6,262.00Low: 6,079.00Yesterday’s Close: 6,204.00

Astrazeneca Plc Ord Shs $0.25

Astrazeneca is listed in the FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Astrazeneca is part of the Medicine and Biotech Research sector

Global Pharmaceutical company with 6700 employees across 7 sites in the UK. AstraZeneca work with the NHS, UK healthcare professionals, government and policy makers and patient groups. Market cap £65.05bn.





Share Price SpacerPrice
6204.00
Share Price SpacerBid
6207.00
Share Price SpacerAsk
6208.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
3,220,642
Share Price SpacerOpen
6,182.00
Share Price SpacerHigh
6,262.00
Share Price SpacerLow
6,079.00
Share Price SpacerClose
6,204.00
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 1,266.78m £78,591.34m 300

52 Week High 6,432.00 52 Week High Date 15-NOV-2018
52 Week Low 4,544.50 52 Week Low Date 6-FEB-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
20,481 1,728,388 1,263,717 35.181 176.34 219.10 3.53


London South East Users info for Astrazeneca




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

16-Nov-18
18:45:11
6,190.85
114
Sell* 
6,207.00
6,208.00
7,058
Trade Type:
Ordinary

16-Nov-18
18:45:04
6,166.249
13,722
Sell* 
6,207.00
6,208.00
846.13k
Trade Type:
Ordinary

16-Nov-18
18:45:04
6,099.61
49
Sell* 
6,207.00
6,208.00
2,989
Trade Type:
Ordinary




View more Astrazeneca trades >>

Directors Deals for Astrazeneca (AZN)
Trade DateActionNotifierPriceCurrencyAmountHolding
27-Jul-17Buy
Trade Notifier Information for AstraZeneca
Nazneen Rahman held the position of Non-Executive Director at AstraZeneca at the time of this trade.
 Nazneen Rahman
4335.48GBX46139
27-Jul-17Buy
Trade Notifier Information for AstraZeneca
Philip A J Broadley held the position of Non-Executive Director at AstraZeneca at the time of this trade.
 Philip A J Broadley
4282GBX2,3000
27-Jul-17Buy
Trade Notifier Information for AstraZeneca
Nazneen Rahman held the position of Non-Executive Director at AstraZeneca at the time of this trade.
 Nazneen Rahman
4370.13GBX3939
View more Astrazeneca directors dealings >>


Grayling
Posts: 1,444
Opinion:Hold
Price:6,244.00
Mystic
Fri 09:31
Not great news from the MYSTIC trial they are putting a gloss on it but essentially the combination therapy has failed to meet its primary endpoint of improving overall survival versus standard treatment.
Inkose
Posts: 29
Opinion:No Opinion
Price:6,270.00
AstraZeneca Reports Positive Result
Mon 09:48
LONDON (Alliance News) - AstraZeneca PLC on Monday announced positive results from its diabetes drug study and said the US Food & Drug Administration has accepted regulatory submission for cancer drug Lynparza.

Farxiga, the pharmaceutical company's type-2 diabetes drug, was found to significantly reduce hospitalisation for heart failure or cardiovascular death by 17% versus placebo. This figure comes as a result of Astra's DECLARE-TIMI 58 trial of more than 17,000 patients.

Patients taking Farxiga were also found to have fewer major adverse cardiovascular events, but this was not statistically significant.

"These positive results are clinically relevant to the 425 million people worldwide living with diabetes, of whom those with type-2 diabetes have a two-to-five times greater risk of heart failure along with an increased risk of a heart attack or stroke," said AstraZeneca Vice President Elisabeth Bjork.

"Heart failure survival rates are only 50% after five years from diagnosis, which is why these new findings are so important in broadening our understanding of how to go beyond blood glucose so we may better address this serious and often overlooked cardiovascular complication," Jork added.

In a separate announcement, Astra also said that the FDA has accepted a supplemental new drug application for priority review. If granted approval, this would be the fourth indication for Lynparza in the US.

The supplemental application is for the use of Lynparza as a maintenance therapy in newly-diagnosed patients with BRCA-mutated advanced ovarian cancer. BRCA mutations mean that patients are more likely to develop genetic alterations that could lead to cancer.

If approved, Lynparza's use will be expanded to patients who are have responded to platinum-based chemotherapy, which is the standard treatment in patients with this type of cancer.

The application is based on the results of Astra's phase three SOLO-1 trial, which showed statistically significant and clinically meaningful improvement in progression-free survival over placebo. Risk of disease progression or death in patients was reduced by 70%.

At present, Lynparza has approval in more than 60 countries for the treatment of relapsed ovarian cancer and for a particular kind of breast cancer.

Shares in AstraZeneca were up 1.7% at 6,274.00 pence on Monday morning.
quelfromage1
Posts: 595
Opinion:No Opinion
Price:6,164.00
RE: azn
9 Nov '18
O/T
borgy , out of curiosity did you stop loss out of SMDS?
Abkaz
Posts: 400
Opinion:No Opinion
Price:6,100.00
RE: azn
8 Nov '18
The tortoise wins again!
AL75
Posts: 1,357
Opinion:No Opinion
Price:6,144.00
RE: Results
8 Nov '18
Thanks Grayling.

The market has more sway than the BBC a 5% increase is a big daily gain and it's also just broken 6138 resistance. From July it formed a small bullish rectangle and now the target should be 6750. GLA and DYOR
View more share chat for Astrazeneca (AZN) >>




Astrazeneca Plc Ord Shs $0.25 home pageWebsite: Astrazeneca Plc Ord Shs $0.25
Website Description: Global Pharmaceutical company with 6700 employees across 7 sites in the UK. AstraZeneca work with the NHS, UK healthcare professionals, government and policy makers and patient groups. Market cap £65.05bn.



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.